Abstract
Introduction
Serotonin and norepinephrine reuptake inhibitors (SNRIs) are antidepressants which have high affinity to both serotonin transporter (SERT) and norepinephrine transporter (NET). In studies in vitro, SNRIs have been reported to show a large variability in the affinity ratio between SERT and NET. For instance, the reported affinity ratio is about 30 for venlafaxine and 1.6 for milnacipran. In this study in nonhuman primates, we aimed to investigate the relationship between SERT and NET affinity by measuring the in vivo occupancy at both transporters of venlafaxine and milnacipran.
Methods
PET measurements with [11C]MADAM and [18F]FMeNER-D2 were performed in two female cynomolgus monkeys at baseline and after pretreatment with venlafaxine and milnacipran, respectively. Relationships between dose, plasma concentration, and transporter occupancy were evaluated by saturation analysis using a hyperbolic function. Binding affinity (Kdplasma) was expressed by the dose or plasma concentration at which 50 % of the transporter was occupied.
Results
SERT and NET occupancy by venlafaxine and milnacipran increased in a dose and plasma concentration-dependent manner. The Kdplasma ratio of SERT to NET was 1.9 for venlafaxine and 0.6 for milnacipran.
Conclusions
In this nonhuman primate PET study, the affinity in vivo for SERT and NET, respectively, was shown to be at a similar level for venlafaxine and milnacipran. Both drugs were found to produce balanced inhibition of SERT and NET binding. This observation is not consistent with previous in vitro binding data and illustrates the need to characterize antidepressants at in vivo condition.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871–880
Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH (2006) Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 318:657–665
DeLorenzo C, Lichenstein S, Schaefer K, Dunn J, Marshall R, Organisak L, Kharidia J, Robertson B, Mann JJ, Parsey RV (2007) SEP-225289 serotonin and dopamine transporter occupancy: a PET study. J Nucl Med 52:1150–1155
Farde L, Eriksson L, Blomquist G, Halldin C (1989a) Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET—a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9:696–708
Farde L, Hall H, Ehrin E, Sedvall G (1986) Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231:258–261
Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544
Farde L, Wiesel FA, Nordstrom AL, Sedvall G (1989b) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl) 99(Suppl):S28–S31
Gex-Fabry M, Balant-Gorgia AE, Balant LP, Rudaz S, Veuthey JL, Bertschy G (2004) Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur J Clin Pharmacol 59:883–891
Halldin C, Lundberg J, Sovago J, Gulyas B, Guilloteau D, Vercouillie J, Emond P, Chalon S, Tarkiainen J, Hiltunen J, Farde L (2005) [(11)C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET. Synapse 58:173–183
Hendset M, Haslemo T, Rudberg I, Refsum H, Molden E (2006) The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry 39:121–127
Higuchi H, Yoshida K, Takahashi H, Naito S, Kamata M, Ito K, Sato K, Tsukamoto K, Shimizu T, Nakanishi M, Hishikawa Y (2003) Milnacipran plasma levels and antidepressant response in Japanese major depressive patients. Hum Psychopharmacol 18:255–259
Hynninen VV, Olkkola KT, Bertilsson L, Kurkinen K, Neuvonen PJ, Laine K (2008) Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clin Pharmacol Ther 83:342–348
Karlsson P, Farde L, Halldin C, Swahn CG, Sedvall G, Foged C, Hansen KT, Skrumsager B (1993) PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology (Berl) 113:149–156
Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, Threlkeld PG, Nelson DL, Perry KW, Bymaster FP (2003) Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45:935–944
Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. NeuroImage 4:153–158
Lee CM, Farde L (2006) Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 27:310–316
Machado M, Einarson TR (2010) Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. J Clin Pharm Ther 35:177–188
Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161:826–835
Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM (1996) Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 41:149–156
Rabiner EA, Gunn RN, Wilkins MR, Sedman E, Grasby PM (2002) Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride. J Psychopharmacol 16:195–199
Schou M, Halldin C, Pike VW, Mozley PD, Dobson D, Innis RB, Farde L, Hall H (2005) Post-mortem human brain autoradiography of the norepinephrine transporter using (S, S)-[18 F]FMeNER-D2. Eur Neuropsychopharmacol 15:517–520
Schou M, Halldin C, Sovago J, Pike VW, Hall H, Gulyas B, Mozley PD, Dobson D, Shchukin E, Innis RB, Farde L (2004) PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 53:57–67
Sekine M, Arakawa R, Ito H, Okumura M, Sasaki T, Takahashi H, Takano H, Okubo Y, Halldin C, Suhara T (2010) Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S, S)-[18 F]FMeNER-D2. Psychopharmacology (Berl) 210:331–336
Seneca N, Gulyas B, Varrone A, Schou M, Airaksinen A, Tauscher J, Vandenhende F, Kielbasa W, Farde L, Innis RB, Halldin C (2006) Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S, S)-[18 F]FMeNER-D2. Psychopharmacology (Berl) 188:119–127
Swanson LW, Hartman BK (1975) The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker. J Comp Neurol 163:467–505
Takano A, Gulyas B, Varrone A, Maguire RP, Halldin C (2009) Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S, S)-[(18)F]FMeNER-D (2). Eur J Nucl Med Mol Imaging 36:1308–1314
Takano A, Nag S, Gulyas B, Halldin C, Farde L (2011) NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo. Psychopharmacology (Berl) 216:279–286
Takano A, Suzuki K, Kosaka J, Ota M, Nozaki S, Ikoma Y, Tanada S, Suhara T (2006) A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl) 185:395–399
Thase ME (2008) Are SNRIs more effective than SSRIs? A review of the current state of the controversy. Psychopharmacol Bull 41:58–85
Troy SM, Lucki I, Peirgies AA, Parker VD, Klockowski PM, Chiang ST (1995) Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J Clin Pharmacol 35:410–419
Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L (2009) Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging 36:1639–1650
Watson (2000) New, faster, image-based scatter correction for 3D PET. IEEE Trans Nucl Sci 47:1587–1594
Zeng Z, Chen TB, Miller PJ, Dean D, Tang YS, Sur C, Williams DL Jr (2006) The serotonin transporter in rhesus monkey brain: comparison of DASB and citalopram binding sites. Nucl Med Biol 33:555–563
Acknowledgments
The authors thank all the members of the Karolinska PET group for their assistance in the PET experiments, including a special thanks to Gudrun Nylen for the excellent technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takano, A., Halldin, C. & Farde, L. SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study. Psychopharmacology 226, 147–153 (2013). https://doi.org/10.1007/s00213-012-2901-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-012-2901-z